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Breast cancer continues to be a significant
health threat, with 180,000 new cases and
over 41,000 deaths occurring in the United
States in 2000. Both environmental and heri-
table factors are important in breast disease
development (1). The current generally
accepted surveillance techniques of mammo-
gram and breast exam miss up to 40% of
early breast cancers. New methods of early
detection and prevention are sorely needed.
Nipple aspiration, which noninvasively pro-
vides both breast epithelial cells (the cells that
cause breast cancer) and proteins secreted
from the breast epithelium, has the potential
to be an important new surveillance tool.
The androgen testosterone is associated
with breast cancer risk. Testosterone levels in
serum have long been known to increase
with worsening breast cancer risk and dis-
ease. This association has been consistently
demonstrated in case–control and prospec-
tive studies in postmenopausal subjects
(2–8), whereas the results in premenopausal
women have been inconsistent (5). These
studies of serum and plasma extended evi-
dence of increases in urinary levels of testos-
terone in women with breast cancer (9–11).
Testosterone is also found in nipple aspirate
fluid (NAF) (12) and may be a valuable
marker of risk. The advantage of NAF over
serum is that many proteins are highly con-
centrated compared to corresponding serum
and are breast specific, whereas levels in
serum may be contributed by many organs.
Testosterone is thought to exert a variety
of effects on the breast. These include a)
preferential binding to circulating binding
proteins, thus increasing free estradiol avail-
able to breast cells; b) increasing total estro-
gen levels through aromatic conversion of
testosterone; c) direct stimulation of breast
cells through androgen receptors; and d)
stimulation of other growth factors (2). We
therefore hypothesized that NAF testosterone
may prove to be a marker of breast cancer.
Prostrate-specific antigen (PSA), also
known as human kallikrein 3 (hK3), is a
member of the kallikrein family of glycopro-
teins. It was originally thought to be pro-
duced only by the prostate (13). Functionally,
PSA acts to liquefy seminal coagulum (14).
PSA is the best screening marker available for
prostate cancer (13). PSA is now known to
exist in nonprostatic tissues, including the
breast, lung, ovary, uterus, and pancreas
(15–17). We have determined in a small
cohort that PSA levels in NAF are inversely
associated with breast cancer (18), suggesting
that PSA may be a useful marker to screen
women at risk for the disease. The usefulness
of PSA in the detection and surveillance of
prostate cancer is in the fact that it is easily
measurable in male serum. Unfortunately,
quantifying serum PSA in women has been
difficult because the level of PSA is often
below the detection limit of available meth-
ods. New methods have recently been devel-
oped to detect PSA levels as low as 1 ng/L
(19), levels often found in female serum.
These more sensitive techniques hold the
promise that serum PSA may become useful
in assessing risk or in the diagnosis of breast
cancer (20).
Prostatic PSA is hormonally controlled
(21). Breast PSA is also under hormonal
control (22,23). PSA production is inducible
in cultured T47D breast cancer cells by the
addition of steroid hormones, including
androgens and progestins, to the culture
media (23–25).
In a study by Yu et al. (26), carcinomas,
benign breast disease, and normal breast tis-
sues were extracted and evaluated for PSA
expression. Benign and normal specimens
were collected from women without evi-
dence of cancer. Specimens with benign
breast disease had signiﬁcantly higher levels
of PSA than did carcinoma specimens. What
was not evaluated was PSA expression in his-
tologically benign tissue adjacent to carci-
noma. There is ample evidence to support
the notion that field cancerization exists in
the breast. According to this hypothesis, spe-
ciﬁc aberrations may be present in both can-
cer and normal-appearing adjacent tissue.
The latter changes reflect damage due to
long-term carcinogenic exposure, and they
precede morphologically detectable neoplas-
tic transformation. It has been demonstrated
that chromosomal alterations (27), inhibi-
tion of apoptosis (28), HER-2/neu ampliﬁca-
tion (29), and p53 mutations (30) occur in
histologically benign tissue adjacent to breast
carcinomas. Skip lesions have been identiﬁed
in mammary Paget disease, which is best
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Articles
Preliminary evidence has associated testosterone and prostate-speciﬁc antigen (PSA) with breast
cancer. Our objective was to determine whether a) testosterone levels in nipple aspirate fluid
(NAF), serum, or breast tissue are associated with breast cancer; b) testosterone levels in serum
are associated with levels in NAF; c) PSA in NAF, serum, or breast tissue is associated with breast
cancer; and d) serum PSA is associated with NAF PSA levels. We obtained 342 NAF specimens
from 171 women by means of a modiﬁed breast pump. Additionally, we collected 201 blood sam-
ples from 99 women and 51 tissue samples from 41 subjects who underwent surgical resection for
suspected disease. Women currently using birth control pills or hormone replacement therapy
were excluded from the study. Controlling for age and menopausal status, serum testosterone was
signiﬁcantly increased in women with breast cancer (p = 0.002). NAF and serum testosterone lev-
els were not associated. Neither NAF nor tissue testosterone was associated with breast cancer.
Controlling for menopausal status and age, NAF PSA was signiﬁcantly decreased in women with
breast cancer (p < 0.001). We did not find serum PSA to be associated with breast cancer,
although we found an indication that, in postmenopausal women, its levels were lower in women
with cancer. Serum PSA was associated with NAF PSA in postmenopausal women (p < 0.001).
PSA levels in cancerous tissue were signiﬁcantly lower than in benign breast specimens from sub-
jects without cancer (p = 0.011), whereas levels of PSA in histologically benign specimens from
subjects with cancer were intermediate. Our results suggest that serum testosterone is increased
and NAF PSA is decreased in women with breast cancer, with PSA expression being higher in
normal than in cancerous breast tissues. NAF and serum PSA levels in postmenopausal women
are correlated, suggesting that as laboratory assessment of PSA becomes more sensitive, serum
PSA may become useful in identifying women with breast cancer. Key words: breast cancer, nip-
ple aspirate ﬂuid, prostate-speciﬁc antigen, sex hormones, testosterone. Environ Health Perspect
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Our intention was both to validate the ear-
lier ﬁndings in normal and malignant breast
tissue and to compare PSA expression in
these specimens with expression in histologi-
cally benign tissues adjacent to carcinomas,
which were not evaluated in the earlier
study. We felt that this was important to
give some insight into whether alterations in
PSA expression occur globally in the breast
as a field phenomenon or, rather, occur
speciﬁcally with phenotypic evidence of cel-
lular degeneration to cancer.
Because earlier studies demonstrated that
serum levels of testosterone were associated
with breast cancer (3,7,32), as well as evi-
dence that testosterone was measurable in
NAF (12), we first sought to determine if
testosterone levels in NAF, serum, or tissue
were associated with breast cancer. We next
sought to confirm our earlier findings (12)
that NAF PSA was associated with breast
cancer and to investigate the association
between serum PSA and breast cancer. We
also evaluated the correlation of NAF and
serum levels of both testosterone and PSA.
Finally, we analyzed testosterone and PSA in
benign, cancer adjacent, and cancerous tis-
sues to test the hypothesis that there is a ﬁeld
effect in breast cancer.
No single marker in clinical use is sufﬁ-
ciently sensitive and speciﬁc to detect breast
cancer. Therefore, multiple markers will be
required to optimize our ability to detect dis-
ease at its earliest stage. By expanding the
number of known markers of breast cancer
available in NAF, serum, and/or tissue, we
can add to the current regimen of detection
and surveillance methods and perhaps
reduce the staggering incidence and annual
death rate produced by this disease.
Materials and Methods
Subject and specimen accrual. Between 1995
and 2000, informed consent was secured
from 233 women who enrolled in an
Institutional Review Board-approved study.
The women were between the ages of 24 and
80 years, with 84% whites and 49% pre-
menopausal. Four percent of premenopausal
subjects were taking oral contraceptives, and
15% of postmenopausal women were on
hormone replacement therapy at the time of
enrollment. We categorized the women into
one of seven risk groups: 1) no risk factors, 2)
history of a first degree relative with breast
cancer, 3) history of cancer in the breast con-
tralateral to that being studied, 4) biopsy-
proven atypical hyperplasia, 5) biopsy-proven
lobular carcinoma in situ, 6) biopsy-proven
ductal carcinoma in situ, or 7) biopsy-proven
invasive carcinoma. Subjects who ﬁt into two
risk groups were assigned to the category of
greater risk. Because few women were in risk
categories 2–5, we collapsed categories 0–5
(“noncancer”) and 6 and 7 (“cancer”) for all
analyses.
We attempted to obtain NAF and serum
specimens from all subjects. Some subjects
agreed to provide one or the other specimen,
whereas some subjects provided both. We
collected 342 NAF specimens from 171
women and 201 blood samples from 99
women. In addition, we obtained 51 tissue
samples from 41 subjects who underwent
surgical resection of suspected disease. We
successfully collected serum from all of the
subjects and NAF from 99% of the subjects
who agreed to provide these specimens.
Tissue was obtained when available from all
subjects who underwent breast surgery after
pathologic review in which tissue was classi-
fied as benign (including fibroadenomas,
ﬁbrocystic disease, and histologically normal
tissue), cancer adjacent, or cancerous.
We recorded NAF testosterone and PSA
measures as coming from either the right or
the left breast. Some subjects had measures
from one side only, whereas others had mea-
sures from both sides. For subjects who had
measures from both sides (8 for NAF testos-
terone and 17 for NAF PSA), we randomly
selected one side for the analyses (along with
the corresponding side-specific cancer risk
assessment). If multiple testosterone or PSA
measures were available from serum or for
NAF from the selected side, we collapsed
them into a single value (their median). For
the tissue analyses, some women with cancer
had measures available for both cancerous
and cancer-adjacent tissue. In those cases, we
only used the cancer-adjacent tissue data.
We used only one measurement per woman
in each analysis.
Nipple aspiration technique. We per-
formed nipple aspiration using a modified
breast pump after obtaining informed con-
sent. The technique has previously been
described (18). Briefly, we warmed the
breasts with moist towels. The subject then
massaged her breasts for approximately 2
min. We cleansed her nipples with a mild
soap followed by alcohol. We then placed a
suction device first over the right breast (if
present) and then over the left breast.
Suction was created using a 10 cc syringe,
which we held for 10–15 sec or until the
participant experienced discomfort. We col-
lected the ﬂuid, which appeared in the form
of droplets, into glass capillary tubes.
Testosterone assays of NAF, serum, and
tissue. We prepared NAF, serum, and tissue
specimens in a fashion similar to that
described for PSA (see below). For measuring
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Table 1. NAF and serum testosterone and PSA among cancer and noncancer specimens.
Noncancer Cancer
Age (years) Subjects (n) Median (range) Subjects (n) Median (range)
Testosterone in NAF (µg/g)
Premenopausal
< 42 3 7.0 (3.5–14.5) 6 16.5 (10–62)
≥ 42 8 13.0 (0–192) 7 11.5 (4–53)
Postmenopausal
< 60 3 6.0 (1–25) 8 8.5 (3–12)
≥ 60 0 NA 16 11.0  (0–229)
Total 14 11.0 (0–192) 37 11.0 (0–229)
Testosterone in serum (ng/mL)*
Premenopausal
< 42 7 49.0 (37–59) 6 64.5 (47–108)
≥ 42 10 55.0 (36.5–68) 8 60.0 (40–78)
Postmenopausal
< 60 6 38.0 (27–54) 11 58.0 (44–93)
≥ 60 1 62.0 (62–62) 16 59.5 (32–156)
Total 24 50.5 (27–68) 41 59.0 (32–156)
NAF PSA (ng/g) **
Premenopausal
< 42 16 982.0 (19–8,176) 23 37.0 (0–9,812)
≥ 42 21 2037.5 (1–4,569) 20 110.8 (0–5,684)
Postmenopausal
< 60 16 163.0 (31–13,423) 16 69.0 (0–2,522)
≥ 60 1 340.0 (340–340) 38 31.5 (0–12,408)
Total 54 851.0 (1–13,423) 97 49.0 (0–12,408)
Serum PSA (ng/L)
Premenopausal
< 42 12 0.3 (0–11) 6 4.5 (0–21)
≥ 42 11 1.0 (0–24) 9 2.0 (0–13)
Postmenopausal
< 60 9 8.0 (0–63) 11 0.0 (0–19)
≥ 60 2 1.0 (0–2) 17 0.0 (0–34)
Total 34 1.0 (0–63) 43 1.0 (0–34)
NA, not available. 
*p = 0.002; **p < 0.001 (comparison of cancer vs. noncancer across all four menopause/age strata).testosterone levels, we used a commercially
available kit on an ACS180 Immunochemistry
Analyzer (Bayer Diagnostics, Tarrytown, NY).
PSA studies of NAF, serum, and tissue.
We determined NAF total protein content
using a Pierce BCA Protein Assay Reagent
Kit (Rockford, IL) and analyzed PSA as pre-
viously described (19). Brieﬂy, this procedure
combines a time-resolved immunoﬂuoromet-
ric assay with two monoclonal antibodies and
has a detection limit of 1 ng/L. For NAF, the
capillary tubes containing the specimen were
broken in half and placed in 400 µL of a 0.1
M NaHCO3 solution, pH 7.80. We then
crushed the capillary tube with a steel spat-
ula to release the NAF. Breast tissue was
snap frozen in liquid nitrogen, pulverized,
and homogenized. The specimen was then
centrifuged, and the cytosol extract was col-
lected using lysis buffer as previously
described (26). We then aliquoted the serum
samples, leaving behind the cellular fraction.
The coefficients of variation for both the
PSA and testosterone assays were < 10%
within the measurement range. We stored
samples for analysis at –80°C and batched
them for analysis. We performed all analyses
under the supervision of a laboratory admin-
istrator with over 20 years of experience.
Technicians were blinded to the risk group
of each sample.
Statistical analyses. In assessing the asso-
ciation of NAF and serum testosterone and
PSA with breast cancer, we had planned to
control for potential confounders, including
menopausal status, age, oral contraceptive
use, and hormone replacement therapy.
However, in our data only a small number
of women were currently on birth control
pills (n = 4) or hormone replacement ther-
apy (n = 12). This made it impossible to
control for these factors via statistical adjust-
ment. We therefore decided to exclude those
few women on birth control pills or hor-
mone replacement therapy from our analyses
of NAF and serum testosterone and PSA.
We compared the cancer and noncancer
groups with respect to NAF or serum testos-
terone and PSA, using the exact version of
the stratified Wilcoxon two-sample test.
Menopausal status and age formed the strata
(with age dichotomized at the median, sepa-
rately for the premenopausal and post-
menopausal groups). The stratiﬁed Wilcoxon
test is the nonparametric equivalent of an
analysis of variance model, with main effects
for menopause and age (but no interaction
terms) included. It is a distribution-free test;
that is, it does not require an assumption of
normality for the testosterone and PSA mea-
sures. We measured the association between
the levels of testosterone or PSA in NAF and
serum with the nonparametric Spearman
correlation coefﬁcient. Finally, we compared
testosterone and PSA levels across various
types of tissues (benign vs. cancer-adjacent vs.
cancerous) using the nonparametric Kruskal-
Wallis test. Because of the small sample size
for which tissue measures were available,
these analyses did not control for any other
factors. We used SAS 8.0 (SAS Institute,
Inc., Cary, NC) and StatXact-4 (Cytel
Software Corporation, Cambridge, MA) for
the analyses. 
Results
We ﬁrst present results from the investigation
of the association of NAF and serum testos-
terone and PSA with breast cancer status
(cancer vs. noncancer). These analyses con-
trol for menopausal status and age. However,
because of the small number of older post-
menopausal women without cancer, we are
not conﬁdent that our results can be extrap-
olated to that group. We next present the
correlations between the NAF and serum
measures, separately for premenopausal and
postmenopausal women. The final set of
results pertains to the comparison of cancer-
ous, cancer-adjacent, and normal tissue with
respect to testosterone and PSA levels. Those
analyses do not control for any covariates.
Testosterone in NAF and serum.
Testosterone levels in NAF ranged from 0 to
229 µg/g, with a median value of 11 µg/g
(Table 1). Controlling for menopausal status
and age, NAF testosterone was not associated
with breast cancer (p = 0.597). Serum levels
of testosterone were uniformly measurable,
unlike PSA (see below). Values ranged from
21 to 156 ng/mL (Table 1). Controlling for
menopausal status and age, we found a statis-
tically signiﬁcant difference in serum testos-
terone between women with and without
cancer (p = 0.002), with serum testosterone
levels higher in women with cancer across all
strata (Figure 1). In post hoc testing, the dif-
ference in serum testosterone between
women with and without cancer was not sig-
nificant in premenopausal women (p =
0.059) but was signiﬁcant in postmenopausal
women (p = 0.015). The significant differ-
ence was mainly attributable to the post-
menopausal group < 60 years of age. Only
one noncancer subject was ≥ 60 years old, so
we are uncertain if a difference exists in the
latter group.
We found no statistically signiﬁcant cor-
relation between NAF and serum testos-
terone in either 15 premenopausal women or
in 11 postmenopausal women who had both
measures available. In both premenopausal
and postmenopausal groups, however, we
found an indication of an inverse association
(Spearman correlations of –0.44, p = 0.105,
in premenopausal women and –0.38, p =
0.252, in postmenopausal women).
PSA in NAF and serum. PSA in NAF
ranged from 0 to 13,423 ng/g of total pro-
tein (Table 1). Controlling for menopausal
status and age, we found a signiﬁcant differ-
ence in NAF PSA levels between the cancer
and noncancer groups (p < 0.001; Table 1).
PSA levels in NAF were substantially lower
in breasts with cancer than in breasts with-
out cancer across all strata defined by
menopausal status and age (Figure 2). In
post hoc testing, the difference in NAF PSA
between women with and without cancer
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Figure 1. Box plots of serum testosterone levels for the cancer and noncancer groups by menopausal sta-
tus and age. Boxes indicate 25th and 75th percentiles, solid lines inside boxes indicate median; error bars
indicate minimum and maximum, and circles indicate outliers. One extreme observation (156 ng/mL) has
been omitted from the postmenopausal ≥ 60 years group.
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< 0.001) but not in postmenopausal women
(p = 0.059). The latter results are inconclu-
sive for older postmenopausal women
because only one NAF PSA measure was
available from a noncancerous breast.
Although NAF has the theoretical
advantage over serum of being breast spe-
cific, we were not sure which physiologic
ﬂuid would prove to be the better source of
PSA. We therefore wondered if serum PSA
was routinely detectable in women, if it was
associated with NAF PSA, and whether it
was associated with breast cancer. Serum
PSA levels ranged from 0 to 63 ng/L (with
undetectable levels in 39% of the samples).
Controlling for menopausal status and age,
we did not find a significant difference in
serum PSA levels between women with and
without cancer (p = 0.744). Post hoc analysis
suggests, however, that in premenopausal
women serum PSA tends to be higher in
women with cancer (p = 0.156), whereas in
postmenopausal women serum PSA is higher
in those without cancer (p = 0.044; see
medians in Table 1). The apparent different
direction of the association is suggestive of
an interaction based upon a subject’s
menopausal status, but our sample size is too
small for any reliable conclusions regarding
this matter.
We evaluated the association between
serum and NAF PSA levels in 25 pre-
menopausal and 20 postmenopausal women
who had both serum and NAF measures
available. This association was high and sig-
nificant in the postmenopausal group
(Spearman correlation coefﬁcient of 0.71, p
< 0.001), but not in the premenopausal
group (Spearman correlation coefficient of
0.18, p = 0.385).
Testosterone and PSA in tissue. Tissue
levels of PSA ranged from 1 to 1,369 ng/g
and were signiﬁcantly different in the differ-
ent tissue types (p = 0.024; Table 2).
Although the PSA levels in cancer-adjacent
tissue were not significantly different from
the PSA levels in benign tissue (p = 0.172) or
cancerous tissue (p = 0.068), PSA was higher
in benign tissue from women without cancer
than in cancerous specimens (p = 0.011).
Tissue levels of testosterone ranged from 2
to 88 mg/g and were not signiﬁcantly differ-
ent in cancerous, cancer-adjacent, and
benign breast tissue (p = 0.787; Table 2).
Discussion
Despite intense research and prevention
efforts, breast cancer remains the most
prevalent cancer in U.S. women. The best
current surveillance regimen (mammogram,
breast self-exam, and physical exam by a
health care provider) still misses a signiﬁcant
percentage of early cancers. New detection
methods to identify patients with the disease
must be developed. Nipple aspiration shows
promise as a valuable adjunct to existing pro-
cedures. In addition, advances in laboratory
techniques may bring value to known mark-
ers previously thought worthless for the
diagnosis and surveillance of breast cancer.
More valuable than any one of these tests is
the combination of results. Thus, new mark-
ers must always be sought.
Nipple aspiration is a quick and painless
method of obtaining breast epithelial cells and
the ﬂuid they secrete. In our quest to develop
new candidate markers in NAF, we evaluated
testosterone, knowing its proven association
in serum with postmenopausal breast cancer.
We conﬁrmed that, controlling for age and
menopausal status, the levels of circulating
testosterone were significantly higher in
women with breast cancer compared to
women without cancer. We observed this
association in both premenopausal and post-
menopausal women, although we did not
have enough women ≥ 60 years of age with-
out cancer to make accurate inferences for this
group. We were not able to demonstrate an
association between circulating testosterone
and NAF testosterone levels. Likewise, we did
not observe an association between NAF or
tissue testosterone levels and breast cancer.
However, all of these analyses may have lim-
ited power due to the small sample size.
A limitation of our study is that we mea-
sured only total testosterone. Whether the
free or albumin-bound fraction is more rele-
vant biologically is a matter of debate (2,33).
We elected to analyze total testosterone in
order to be able to compare our results with
other reports because most have elected to
analyze the total hormone. Of note, one of
the studies that did ﬁnd signiﬁcantly higher
levels of circulating testosterone in pre-
menopausal women with breast cancer eval-
uated the free fraction (32).
In this study, we conﬁrmed our previous
findings that NAF PSA is inversely associ-
ated with breast cancer (18). We also deter-
mined that levels of PSA in NAF are
associated with PSA levels in serum in post-
menopausal women. Markers in NAF and
serum have been compared in the past,
showing increases in both serum and breast
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Table 2. Testosterone and PSA in tissue with and without breast cancer.
Specimen type Subjects Median (range)
Testosterone (mg/g)
Benign tissue  5 5 (3–13)
Cancer-adjacent tissue 10 6 (2–88)
Cancer 11 5 (2–54)
PSA (ng/g)*
Benign tissue  7 88.0 (7–598)
Cancer-adjacent tissue 18 26.5 (1–3,733)
Cancer 16 5.0 (0–1,369)
*p = 0.024 (Kruskal-Wallis test).
Figure 2. Box plots of log NAF PSA levels for the cancer and noncancer groups by menopausal status and
age. Boxes indicate 25th and 75th percentiles, solid lines inside boxes indicate median; error bars indi-
cate minimum and maximum, and circles indicate outliers.
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)fluid levels of lactogenic hormones in
women with cystic breast disease (34). This
comparison is of interest to this investigation
in hopes that an association between NAF
and serum levels of PSA would extend to an
association between circulating PSA levels
and breast cancer. Thus, serum PSA could
possibly become as helpful to screen women
for breast cancer as it has to screen men for
prostate cancer.
We did not find a significant overall
association between serum PSA and breast
cancer, although this may be due to the fact
that this association appears to be different
in premenopausal and postmenopausal
women. Among premenopausal women we
observed a nonsignificant trend toward
higher serum PSA in women with cancer,
whereas among postmenopausal women
serum PSA levels were signiﬁcantly higher in
those without cancer. PSA levels in the
blood of normal men are lower than in men
with prostate cancer, yet gland levels are
higher in normal males (35). It appears that
PSA expression in premenopausal women
may mimic the pattern in males, with breast-
specific (both NAF and tissue) PSA being
higher and serum PSA being lower in nor-
mal women than in those with breast cancer.
On the other hand, there is a direct relation-
ship in postmenopausal women, with lower
PSA levels in both NAF and serum being
found in those with breast cancer. This dif-
ference is likely due to the inﬂuence of ovar-
ian hormones and the relative levels of PSA
found in the breast of premenopausal versus
postmenopausal women, but larger studies
are needed to clarify this.
PSA is highly concentrated in NAF,
often at concentrations much higher than in
serum (up to 10,000-fold) and is readily
measured with currently available assays.
The fact that NAF PSA also appears to be
associated with breast cancer makes it a
potentially valuable marker for this disease.
In a recent report, Zhao et al. (36) evalu-
ated the association of PSA in NAF with
breast cancer. The investigators were success-
ful in collecting NAF from 34% of subjects,
and had adequate NAF to perform analyses
in 29.6% of subjects who consented to
undergo aspiration. The authors observed
similar levels of PSA in tumor-free breasts
and in those recently diagnosed with breast
cancer. Zhao et al. (36) speculated that the
difference we observed (18) was due to
hemodilution in the NAF collected from
mastectomy specimens resulting in lower
PSA levels. We are not sure why the results
of the two studies differ, but we do not
believe it is due to hemodilution. We rou-
tinely evaluate our NAF specimens for the
presence of red blood cells. Thirty-two of the
110 NAF specimens in this study obtained
from subjects with breast cancer contained
red blood cells. We found no statistically sig-
niﬁcant difference in NAF PSA levels in the
specimens with versus without blood from
subjects with breast cancer, whether we con-
sidered the overall sample or premenopausal
or postmenopausal women separately. When
we eliminated specimens containing blood
and compared PSA levels in women with
and without breast cancer, controlling for
menopausal status and age, we found that
PSA was significantly lower in NAF from
the breasts with cancer than from the breasts
without cancer (p < 0.001). We therefore
speculate that the difference in the ﬁndings
may lie in the population studied, because
we were able to collect NAF from 99% of
the subjects who enrolled in this study,
whereas NAF was obtained from 34% of
those enrolled in the other study (34).
Because NAF was obtained from only a sub-
set of subjects in the other study, the results
may not reflect the entire enrolled popula-
tion. Further studies will help to determine
the usefulness of NAF PSA to predict which
women have or will develop breast cancer.
The concept of ﬁeld cancerization is well
demonstrated in the aerodigestive tract,
where cigarette smoking puts all areas
exposed to the carcinogens in tobacco smoke
at risk. Although the environmental carcino-
gens responsible for inducing and potentiat-
ing the development of breast cancer are not
well defined, there is increasing evidence
that, with perhaps the exception of cancers
that develop in women who have mutations
in high penetrance susceptibility genes such
as BRCA1 and BRCA2, environmental car-
cinogens are important to the development
of cancers of the breast (37,38). We evalu-
ated cancerous breast tissue, histologically
benign tissue adjacent to cancer, and benign
breast tissue from subjects without cancer.
We observed that PSA was significantly
higher in the benign tissue from women
without breast cancer than it was in cancer-
ous tissue. The difference in the median level
of PSA (88 in benign vs. 5 ng/g in cancer)
was quite striking. Although the PSA expres-
sion in the histologically benign but cancer-
adjacent tissue was not statistically greater
than in malignant tissues, the median values
(26 in cancer adjacent vs. 5 ng/g in cancer)
suggest that the difference might be signiﬁ-
cant if the analysis were not limited by sam-
ple size. These preliminary findings suggest
that PSA alterations may occur as a field
effect, in response to a carcinogenic insult.
As more candidate markers are studied,
nipple aspiration shows increasing potential
as a helpful adjunct to existing breast cancer
screening. Just as interesting is the develop-
ment of new markers in serum to enhance
the predictive value of the armament of tests
currently performed. Serum levels of testos-
terone, especially in postmenopausal women
< 60 years of age, may prove to be an impor-
tant marker of breast cancer. To date, PSA
has not yet proven itself in this medium, but
may become useful as detection techniques
improve.
REFERENCES AND NOTES
1. Lichtenstein P, Holm NV, Verkasalo PK, Iliadou A, Kaprio
J, Koskenvuo M, Pukkala E, Skytthe A, Hemminki K.
Environmental and heritable factors in the causation of
cancer—analyses of cohorts of twins from Sweden,
Denmark, and Finland. N Engl J Med 343:78–85 (2000). 
2. Zeleniuch-Jacquotte A, Bruning PF, Bonfrer JM, Koenig
KL, Shore RE, Kim MY, Pasternack BS, Toniolo P. Relation
of serum levels of testosterone and dehydroepiandros-
terone sulfate to risk of breast cancer in postmenopausal
women. Am J Epidemiol 145:1030–1038 (1997).
3. Secreto G, Recchione C, Cavalleri A, Miraglia M, Dati V.
Circulating levels of testosterone, 17 beta-oestradiol,
luteinising hormone and prolactin in postmenopausal
breast cancer patients. Br J Cancer 47:269–275 (1983).
4. Hankinson SE, Willett WC, Manson JE, Colditz GA, Hunter
DJ, Spiegelman D, Barbieri RL, Speizer F. Plasma sex
steroid hormone levels and risk of breast cancer in post-
menopausal women. J Natl Cancer Inst 90:1292–1299
(1998).
5. Thomas HV, Key TJ, Allen DS, Moore JW, Dowsett M,
Fentiman IS, Wang DY. A prospective study of endoge-
nous serum hormone concentrations and breast cancer
risk in premenopausal women on the island of Guernsey.
Br J Cancer 75:1075–1079 (1997).
6. Dorgan JF, Longcope C, Stanczyk FZ, Stephenson HE Jr,
Hoover RN. Re: Plasma sex steroid hormone levels and
risk of breast cancer in postmenopausal women [Letter].
J Natl Cancer Inst 91:380–381 (1999).
7. Dorgan JF, Longcope C, Stephenson HE Jr, Falk RT,
Miller R, Franz C, Kahle L, Campbell WS, Tangrea JA,
Schatzkin A. Serum sex hormone levels are related to
breast cancer risk in postmenopausal women. Environ
Health Perspect 105(suppl 3):583–585 (1997).
8. Berrino F, Muti P, Micheli A, Bolelli G, Krogh V, Sciajno
R, Pisani P, Panico S, Secreto G. Serum sex hormone
levels after menopause and subsequent breast cancer. J
Natl Cancer Inst 88:291–296 (1996).
9. Secreto G, Fariselli G, Bandieramonte G, Recchione C,
Dati V, Di Pietro S. Androgen excretion in women with a
family history of breast cancer or with epithelial hyper-
plasia or cancer of the breast. Eur J Cancer Clin Oncol
19:5–10 (1983).
10. Grattarola R, Secreto G, Recchione C. Androgens in
breast cancer. III. Breast cancer recurrences years after
mastectomy and increased androgenic activity. Am J
Obstet Gynecol 121:169–172 (1975).
11. Grattarola R, Secreto G, Recchione C, Castellini W.
Androgens in breast cancer. II. Endometrial adenocarci-
noma and breast cancer in married postmenopausal
women. Am J Obstet Gynecol 118:173–178 (1974).
12. Sauter ER, Ehya H, Babb J, Diamandis E, Daly M, Klein-
Szanto A, Sigurdson E, Hoffman J, Malick J, Engstrom
PF. Biological markers of risk in nipple aspirate ﬂuid are
associated with residual cancer and tumour size. Br J
Cancer 81:1222–1227 (1999).
13. Diamandis EP. Prostate speciﬁc antigen—its usefulness
in clinical medicine. Trends Endocrinol Metab 9:310–316
(1998).
14. Oesterling JE. Prostate specific antigen: a critical
assessment of the most useful tumor marker for adeno-
carcinoma of the prostate. J Urol 145:907–923 (1991).
15. Diamandis EP, Yu H. Non-prostatic sources of prostate-
specific antigen. In: The Urologic Clinics of North
America (Oesterling JE, ed). Philadelphia:W.B. Saunders,
1997;275–282.
16. Diamandis EP, Yu H. New biological functions of
prostate-specific antigen? [Editorial]. J Clin Endocrinol
Metab 80:1515–1517 (1995).
17. Black MH, Diamandis EP. The diagnostic and prognostic
utility of prostate-specific antigen for diseases of the
breast. Breast Cancer Res Treat 59:1–14 (2000).
Articles • Testosterone and PSA in the breast
Environmental Health Perspectives • VOLUME 110 | NUMBER 3 | March 2002 24518. Sauter ER, Daly M, Linahan K, Ehya H, Engstrom PF,
Bonney G, Ross EA, Yu H, Diamandis E. Prostate-speciﬁc
antigen levels in nipple aspirate fluid correlate with
breast cancer risk. Cancer Epidemiol Biomarkers Prev
5:967–970 (1996).
19. Ferguson RA, Yu H, Kalyvas M, Zammit S, Diamandis EP.
Ultrasensitive detection of prostate-speciﬁc antigen by a
time-resolved immunofluorometric assay and the
Immulite immunochemiluminescent third-generation
assay: potential applications in prostate and breast can-
cers. Clin Chem 42:675–684 (1996).
20. Black MH, Giai M, Ponzone R, Sismondi P, Yu H,
Diamandis EP. Serum total and free prostate-specific
antigen for breast cancer diagnosis in women. Clin
Cancer Res 6:467–473 (2000).
21. Armbruster DA. Prostate-speciﬁc antigen: biochemistry,
analytical methods, and clinical application. Clin Chem
39:181–195 (1993).
22. Zarghami N, Grass L, Diamandis EP. Steroid hormone
regulation of prostate-specific antigen gene expression
in breast cancer. Br J Cancer 75:579–588 (1997).
23. Magklara A, Grass L, Diamandis EP. Differential steroid
hormone regulation of human glandular kallikrein (hK2)
and prostate-speciﬁc antigen (PSA) in breast cancer cell
lines. Breast Cancer Res Treat 59:263–270 (2000).
24. Yu H, Diamandis EP, Zarghami N, Grass L. Induction of
prostate specific antigen production by steroids and
tamoxifen in breast cancer cell lines. Breast Cancer Res
Treat 32:291–300 (1994).
25. Zarghami N, D’Costa M, Tsuyuki D, Asa SL, Diamandis EP.
Expression of the prostate speciﬁc antigen gene by lung
tissue. Clin Cancer Res 3:1201–1206 (1997).
26. Yu H, Diamandis EP, Levesque M, Giai M, Roagna R,
Ponzone R, Sismondi P, Monne M, Croce CM. Prostate
speciﬁc antigen in breast cancer, benign breast disease
and normal breast tissue. Breast Cancer Res Treat
40:171–178 (1996).
27. Botti C, Pescatore B, Mottolese M, Sciarretta F, Greco C,
Di Filippo F, Gandolfo GM, Cavaliere F, Bovani R,
Varanese A, Cianciulli AM. Incidence of chromosomes 1
and 17 aneusomy in breast cancer and adjacent tissue:
an interphase cytogenetic study. J Am Coll Surg
190:530–539 (2000).
28. Hassan HI, Walker RA. Decreased apoptosis in non-
involved tissue from cancer-containing breasts. J Pathol
184:258–264 (1998).
29. Stark A, Hulka BS, Joens S, Novotny D, Thor AD, Wold LE,
Schell MJ, Melton LJ III, Liu ET, Conway K. HER-2/neu
ampliﬁcation in benign breast disease and the risk of sub-
sequent breast cancer. J Clin Oncol 18:267–274 (2000).
30. Kandel R, Li SQ, Ozcelik H, Rohan T. p53 protein accumu-
lation and mutations in normal and benign breast tissue.
Int J Cancer 87:73–78 (2000).
31. Mai KT. Morphological evidence for field effect as a
mechanism for tumour spread in mammary Paget’s dis-
ease. Histopathology 35:567–576 (1999).
32. Secreto G, Recchione C, Fariselli G, Di Pietro S. High
testosterone and low progesterone circulating levels in
premenopausal patients with hyperplasia and cancer of
the breast. Cancer Res 44:841–844 (1984).
33. Pardridge WM. Transport of protein-bound hormones
into tissues in vivo. Endocr Rev 2:103–123 (1981).
34. Rose DP, Berke B, Cohen LA, Lahti HA. A comparison of
serum and breast duct ﬂuid-immunoassayable prolactin
and growth hormone with bioassayable lactogenic hor-
mones in healthy women and patients with cystic breast
disease. Cancer 60:2761–2765 (1987).
35. Darson MF, Pacelli A, Roche P, Rittenhouse HG, Wolfert
RL, Young CY, Klee GG, Tindall DJ, Bostwick DG. Human
glandular kallikrein 2 (hK2) expression in prostatic
intraepithelial neoplasia and adenocarcinoma: a novel
prostate cancer marker. Urology 49:857–862 (1997).
36. Zhao Y, Verselis SJ, Klar N, Sadowsky NL, Kaelin CM,
Smith B, Foretova L, Li FP. Nipple ﬂuid carcinoembryonic
antigen and prostate-speciﬁc antigen in cancer-bearing
and tumor-free breasts. J Clin Oncol 19:1462–1467 (2001).
37. Gammon MD, Hibshoosh H, Terry MB, Bose S,
Schoenberg JB, Brinton LA, Bernstein JL, Thompson
WD. Cigarette smoking and other risk factors in relation
to p53 expression in breast cancer among young women.
Cancer Epidemiol Biomarkers Prev 8:255–263 (1999).
38. Malejka-Giganti D, Niehans GA, Reichert MA, Bennett
KK, Bliss RL. Potent carcinogenicity of 2,7-dinitrofluo-
rene, an environmental pollutant, for the mammary gland
of female Sprague-Dawley rats. Carcinogenesis
20:2017–2023 (1999).
Articles • Sauter et al.
246 VOLUME 110 | NUMBER 3 | March 2002 • Environmental Health Perspectives
To be sure to continue receiving your subscription,call 1.800.315.3010
Address Change? Address Change?